LifeSci Capital downgraded Ventyx Biosciences (VTYX) to Market Perform from Outperform with a $14 price target after the company agreed to be acquired by Eli Lilly for $14 per share.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Hold Rating on Ventyx Biosciences Reflects Limited Upside Amid Eli Lilly All‑Cash Acquisition at $14 per Share
- Ventyx Biosciences downgraded to Hold from Buy at Clear Street
- Eli Lilly to Acquire Ventyx Biosciences in Cash Deal
- Eli Lilly to acquire Ventyx Biosciences for $14.00 per share cash
- Eli Lilly to acquire Ventyx Biosciences for $14.00 per share in cash